Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 30, 2021OncoTargets and TherapyOpen Access

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

HIHassaan ImtiazKing Edward Medical UniversityMKMaimoona KhanPunjab Medical CollegeHEHamid EhsanLevine Cancer Institute

Discussion

Loading...

Member takes

Implication

Systematic review reveals high response rates but notable cardiovascular toxicity for carfilzomib regimens in newly diagnosed multiple myeloma, highlighting the need for phase III trials.

Key Points

  • To evaluate the clinical efficacy and toxicity profile of carfilzomib-based combination regimens as front-line therapy in newly diagnosed multiple myeloma.
  • Systematic review of 27 studies comprising 4,538 patients with newly diagnosed multiple myeloma.
  • Assessed two- and three-drug induction regimens combining carfilzomib with immunomodulators, alkylating agents, monoclonal antibodies, and dexamethasone.
  • Overall response rates ranged between 80% and 100% across regimens, with carfilzomib plus daratumumab combinations reaching an overall response rate of approximately 100%.
  • Minimal residual disease negativity by multi-parameter flow cytometry was achieved in 60% to 95% of patients across four studies reporting this metric (n=251).
  • Interim ENDURANCE trial data showed carfilzomib-lenalidomide did not demonstrate superior progression-free survival over bortezomib-lenalidomide, while hematological toxicities, cardiovascular events, and electrolyte disturbances were the most prominent adverse effects.

Cite This Study

Imtiaz et al. (2021) studied this question.

synapsesocial.com/papers/6a12f20e5bb7edc7189e8275https://doi.org/10.2147/ott.s317570
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)2018 · 89 citations
  2. 2Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study2017 · 26 citations
  3. 3Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial2020 · 703 citations
  4. 4Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)2019 · 77 citations